$-0.11 EPS Expected for Regulus Therapeutics Inc. (RGLS)

October 13, 2018 - By Ruchi Gupta

Regulus Therapeutics Inc. (NASDAQ:RGLS) LogoInvestors sentiment decreased to 0.68 in Q2 2018. Its down 0.43, from 1.11 in 2018Q1. It is negative, as 7 investors sold Regulus Therapeutics Inc. shares while 12 reduced holdings. 7 funds opened positions while 6 raised stakes. 49.70 million shares or 2.00% less from 50.71 million shares in 2018Q1 were reported.
Hightower Advsrs Llc stated it has 22,475 shares or 0% of all its holdings. Morgan Stanley reported 0% stake. Bnp Paribas Arbitrage invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Goldman Sachs Group Inc invested in 16,670 shares. State Street Corporation has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Blackrock Incorporated accumulated 585,357 shares or 0% of the stock. Sweden-based Rhenman Asset Management Ab has invested 0.03% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Bvf Il accumulated 13.69M shares or 0.88% of the stock. Geode Cap Mgmt Limited Liability Com holds 0% or 483,951 shares. Art Ltd Llc invested 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS). Bourgeon Mgmt Ltd Liability owns 13,304 shares for 0% of their portfolio. Tower Rech (Trc) invested in 19,423 shares or 0% of the stock. Wells Fargo Com Mn owns 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 375,972 shares. 135,000 were reported by Drw Secs. Millennium Ltd Llc has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 24,297 shares.

Analysts expect Regulus Therapeutics Inc. (NASDAQ:RGLS) to report $-0.11 EPS on November, 6.They anticipate $0.07 EPS change or 38.89 % from last quarter’s $-0.18 EPS. After having $-0.13 EPS previously, Regulus Therapeutics Inc.’s analysts see -15.38 % EPS growth. The stock increased 3.17% or $0.06 during the last trading session, reaching $1.95. About 71,365 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 82.14% since October 14, 2017 and is downtrending. It has underperformed by 97.76% the S&P500.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Among 3 analysts covering Regulus (NASDAQ:RGLS), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Regulus had 4 analyst reports since May 17, 2018 according to SRatingsIntel. Wedbush maintained the shares of RGLS in report on Thursday, May 17 with “Buy” rating. The firm earned “Neutral” rating on Tuesday, July 10 by Wedbush. Wells Fargo maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) on Friday, July 6 with “Market Perform” rating. On Friday, July 6 the stock rating was maintained by FBR Capital with “Neutral”.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $17.04 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

More important recent Regulus Therapeutics Inc. (NASDAQ:RGLS) news were published by: Seekingalpha.com which released: “Regulus updates on pipeline; investors unmoved, shares down 7% after hours” on September 26, 2018, also Streetinsider.com published article titled: “Regulus Therapeutics (RGLS) Reports 1-for-12 Reverse Share Split”, Benzinga.com published: “44 Biggest Movers From Yesterday” on October 12, 2018. More interesting news about Regulus Therapeutics Inc. (NASDAQ:RGLS) was released by: Seekingalpha.com and their article: “Regulus Therapeutics reverse splits shares 1:12” with publication date: October 04, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News